INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.305
-0.045 (-3.33%)
Feb 19, 2026, 12:05 PM EST - Market open
INmune Bio Employees
As of December 31, 2024, INmune Bio had 22 total employees, including 13 full-time and 9 part-time employees. The number of employees increased by 5 or 29.41% compared to the previous year.
Employees
22
Change (1Y)
5
Growth (1Y)
29.41%
Revenue / Employee
$2,273
Profits / Employee
-$2,267,591
Market Cap
34.69M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 22 | 5 | 29.41% | 13 | 9 |
| Dec 31, 2023 | 17 | 7 | 70.00% | 11 | 6 |
| Dec 31, 2022 | 10 | 0 | - | 10 | 0 |
| Dec 31, 2021 | 10 | 5 | 100.00% | 10 | 0 |
| Dec 31, 2020 | 5 | 1 | 25.00% | 5 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Aligos Therapeutics | 70 |
| Xilio Therapeutics | 64 |
| Lisata Therapeutics | 26 |
| PDS Biotechnology | 24 |
| Veru Inc. | 20 |
| ABVC BioPharma | 19 |
INMB News
- 9 days ago - INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - GlobeNewsWire
- 23 days ago - INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - GlobeNewsWire
- 2 months ago - Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform - GlobeNewsWire
- 2 months ago - INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients - GlobeNewsWire
- 3 months ago - INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference - GlobeNewsWire
- 3 months ago - INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update - GlobeNewsWire
- 4 months ago - INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 - GlobeNewsWire